SanasMed's Innovative Therapy for Obstructive Hypertrophic Cardiomyopathy Receives FDA Breakthrough Device Designation
Sinus
Cardiovascular Consumables Developer
Congratulations on Sinus's Self-Developed Septal Radiofrequency Ablation System Receiving FDA "Breakthrough Device Designation"”. This important milestone marks a critical step with international influence for the company in the field of treating obstructive hypertrophic cardiomyopathy!
FDA Breakthrough Device Designation is a special channel established by the U.S. Food and Drug Administration (FDA) to promote medical device innovation and accelerate the market entry of innovative medical devices with significant clinical advantages.
Sinus is a global innovative medical technology company focused on major cardiovascular diseases. Since its establishment, it has been committed to driving clinical needs and clinical value, adhering to the concept of "Safe, Effective, Simple, and Accessible," providing innovative solutions for global healthcare. Its current R&D pipeline focuses on heart failure and atrial fibrillation management. Among these, the innovative therapy of the septal radiofrequency ablation system for treating obstructive hypertrophic cardiomyopathy has received FDA Breakthrough Device Designation. In the future, Sinus hopes to bring more Chinese clinical innovation practices to the world stage, benefiting patients globally.
DanLuCapital
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)